$OCS News

JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20

Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares

Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis (NASDAQ:OCS) Beats Q2 Estimates and Advances Late-Stage Neuro-Ophthalmology Pipeline

Oculis Reports Q2 2026 Financial Results and Provides Company Update

HC Wainwright & Co. Maintains Buy on Oculis Holding, Maintains $26 Price Target

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis Data

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $23

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

Baird Maintains Outperform on Oculis Holding, Lowers Price Target to $38

Stifel Maintains Buy on Oculis Holding, Lowers Price Target to $40